Financial Performance - The company's operating revenue for Q1 2023 was RMB 369,386,010.95, representing a year-on-year increase of 36.32%[3] - Net profit attributable to shareholders for the same period was RMB 187,759,654.85, reflecting a significant growth of 49.79% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 184,748,130.28, up by 39.56% compared to the previous year[3] - Basic and diluted earnings per share were both RMB 0.35, an increase of 45.83% year-on-year[3] - The weighted average return on equity was 2.27%, an increase of 0.53 percentage points compared to the previous year[4] - The laboratory services business contributed a net profit of RMB 70,116,300, representing a year-on-year growth of 33.79%[6] - Operating revenue increased by 36.32% due to growth in laboratory services[12] - Net profit attributable to shareholders rose by 49.79%, driven by laboratory services growth and appreciation of biological assets[12] - Basic earnings per share increased by 45.83, reflecting the growth in laboratory services and biological assets[12] - The total comprehensive income for Q1 2023 was approximately CNY 183.31 million, compared to CNY 123.85 million in Q1 2022, marking an increase of around 48.0%[27] - The company reported a significant increase in operating profit, reaching approximately CNY 214.37 million in Q1 2023, compared to CNY 139.83 million in Q1 2022, which is an increase of about 53.2%[25] Cash Flow and Assets - The net cash flow from operating activities was negative at RMB -13,668,184.06, a decline of 118.25% year-on-year[3] - Cash flow from operating activities decreased by 118.25% due to year-end bonuses and tax payments[12] - The company's cash and cash equivalents as of March 31, 2023, were CNY 2,964,912,277.41, slightly up from CNY 2,916,847,629.10 as of December 31, 2022[19] - Total current assets increased to CNY 6,069,406,073.03 as of March 31, 2023, compared to CNY 5,928,405,905.39 at the end of 2022, marking a growth of about 2.4%[19] - Total non-current assets as of March 31, 2023, were CNY 4,478,677,682.25, up from CNY 4,435,809,589.23 at the end of 2022, indicating an increase of approximately 1.0%[20] - Total liabilities as of March 31, 2023, were CNY 2,185,937,338.52, compared to CNY 2,173,349,441.47 at the end of 2022, reflecting a slight increase of about 0.6%[21] - The company's total equity attributable to shareholders increased to CNY 8,355,031,298.11 as of March 31, 2023, from CNY 8,183,701,358.27 at the end of 2022, representing a growth of approximately 2.1%[22] Orders and Market Activity - New orders signed during the period amounted to RMB 570 million, a decrease of approximately 43% year-on-year[16] - The total amount of orders on hand at the end of the reporting period was approximately RMB 4.6 billion[16] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24] Research and Development - Research and development expenses in Q1 2023 amounted to CNY 27,611,585.58, compared to CNY 12,289,064.34 in Q1 2022, reflecting a growth of approximately 125.5%[24] Shareholder Information - The top ten shareholders hold a total of 119,400,452 shares, accounting for 22.29% of total shares[13] - The company has not disclosed any related party relationships among the top shareholders[14]
昭衍新药(06127) - 2023 Q1 - 季度业绩